<DOC>
	<DOCNO>NCT02199236</DOCNO>
	<brief_summary>The purpose study see amount radiation safe give rectal anal cancer patient treat procedure call brachytherapy .</brief_summary>
	<brief_title>Dose Escalation Trial Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy Rectal Anal Cancer Patients With Recurrent Disease Undergoing Non-Operative Management</brief_title>
	<detailed_description />
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically confirm locally residual recurrent cancer rectum anus Prior pelvic EBRT Age &gt; = 18 year ECOG performance status 0 , 1 , 2 At least 4 week prior major surgery radiotherapy Have undergone Surgical , Medical Radiation Oncology evaluation confirm : Eligible infusional 5FU capecitabine Will undergo surgery study disease Able receive HDR brachytherapy ANC ≥ 1.5 cells/mm3 PLT ≥100,000/mm3 Adequate Renal function : Creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 50cc/min Adequate Hepatic function : Bilirubin le 1.5 mg/dL ; ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) AST ALT &lt; 3xULN , &lt; 5x ULN know liver metastases Normal Cardiac function : No active coronary artery disease ; No New York Heart Association class II , III IV disease ; No arrhythmia require treatment Maximum tumor length 7 cm time brachytherapy treatment start Women pregnant . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire treatment period receipt brachytherapy . Male subject must also agree use effective contraception treatment period 1 year completion brachytherapy . Patients concurrent medical psychiatric condition disease , investigator 's judgment , would make inappropriate candidate entry study . Patients concurrent anticancer therapy allow study . Contraindications general anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>High-Dose-Rate Brachytherapy</keyword>
	<keyword>oral capecitabine</keyword>
	<keyword>infusional 5-FU</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>14-104</keyword>
</DOC>